OTC · Biotechnology

Molecular Partners AG (MLLCF) Stock

$3.80 +0.00% OTC: MLLCF Healthcare

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.

Valuation

MetricValue
Price$3.80
Market Cap$142.54M
P/E Ratio-2.13
P/B Ratio1.82
P/S Ratio0.00
EPS (TTM)$-1.65
52-Week High$4.85
52-Week Low$2.25
Dividend Yield—

Financials & Margins

MetricValue
ROE-66.19%
ROA-66.25%
ROCE-70.20%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.05
Current Ratio9.42

Annual Financials (USD)

Metric20212022202320242025
Revenue$9.0M$190.0M$7.0M$5.0M$0
Operating Profit$-63.0M$117.0M$-61.0M$-61.0M$-55.0M
Net Profit$-64.0M$118.0M$-62.0M$-54.0M$-62.0M
EPS$-2.06$3.54$-1.89$-1.63$-1.65
Op Margin-679.7%61.5%-868.3%-1231.7%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$173.0M$262.0M$198.0M$159.0M$102.0M
Total Liabilities$65.0M$27.0M$22.0M$17.0M$22.0M
Cash$72.0M$88.0M$67.0M$64.0M$93.0M
Borrowings$6.0M$5.0M$4.0M$2.0M$4.0M

Latest News

Molecular Partners Doses First Patients in Phase 2 Study of Biliary Tract Cancer Therapy MT Newswires · Jul 16, 2026 Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma GlobeNewswire · Jul 16, 2026 Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference GlobeNewswire · Jul 15, 2026 Molecular Partners Makes Progress on Radiotherapy Cancer Candidates MT Newswires · Jul 6, 2026 Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics GlobeNewswire · Jul 6, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-91.0M$119.0M$-59.0M$-59.0M$-50.0M
Investing Cash Flow$-24.0M$-103.0M$44.0M$40.0M$70.0M
Financing Cash Flow$0$0$0$-2.0M$0
Net Cash Flow$-62.0M$16.0M$-21.0M$-3.0M$-37.0M
Free Cash Flow$-92.0M$117.0M$-60.0M$-60.0M$-50.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-35.08%
Quick Ratio9.42
Interest Coverage-13.75
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held8.47%
Institutions Held44.06%
Institutions Float Held48.14%
Institutional HolderSharesReport Date
Old Mission Capital, LLC11,3472025-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAWHAscend Wellness Holdings, Inc. $0.39 -4.77% -0.60 $78.17M 0.00%
BRIBFBrii Biosciences Limited $0.13 +0.00% -2.71 $90.69M 0.00%
BXPHFBotanix Pharmaceuticals Limited $0.02 -30.23% -0.41 $29.89M 0.00%
HOFBFHofseth BioCare ASA $0.17 +0.00% -3.90 $68.47M 0.00%
IPHYFInnate Pharma S.A. $1.65 +0.00% -2.84 $154.94M 0.00%

About Molecular Partners AG

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Molecular Partners AG is headquartered in CH.

Molecular Partners AG (MLLCF) stock trades at $3.80 with a market capitalization of $142.54M. The stock is valued at a price-to-earnings (P/E) ratio of -2.13, price-to-book of 1.82, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.25 and $4.85, and currently trades 21.6% below its 52-week high.

On profitability, Molecular Partners AG generates a return on equity (ROE) of -66.19%, return on capital employed of -70.20%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.molecularpartners.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides